Well, it’s possible the conversations here are all part of the solution that AURYN comes up with. The forum would be rather dull if differing ideas aren’t presented for consideration. I agree with your ratios, but not the premise you are using for arriving at your figures. The PPS determined by the market is not a static figure.
Let’s say for simplicity the 100M share structure is what AURYN stays with and debuts at $1 per share. This is just a hypothetical. Using your same figures, CDCH ends up worth 0.0167 ($5M/300M shares) and MDMN gets 0.009 ($25M/2.8B shares) per share. Of course, these aren’t the figures that are actually going to occur. What the market is valuing both of these stocks currently does not necessarily represent what occurs when a prospectus or registration statement outlines the current status and future prospects for AURYN. Add to that, Medinah’s eventual resolution of legal matters reducing uncertainity. Suppose the path of last resort (perhaps the easiest, but not best) occurs and AURYN uses the CDCH vehicle to become publicly trading. What premium should/could CDCH shareholders receive for use of “the shell” company with a new ticker assigned? No one here has been 100% in predicting any of the last few years.
It is not written in stone how AURYN becomes free-trading or what future factors will be revealed to determine market value of AURYN when it debuts. What happens when AURYN debuts is TBD … do we end up with 2 stocks or 3? Does all trading stop with a buyout (doubtful) of both stocks, or will there be a transition with dividends as CDCH and MDMN or absorbed into AURYN?